RIOK1 synergizes with TRIP13 by regulating the E2F-Rb signaling pathway to promote the proliferation of esophageal cancer cells  

作　　者：Chengyu Li Deyuan Pan Wan Lin Danxia Deng Yingxin Zhou Hui Zhao Feng Pan Liyan Xu Enmin Li Lin Long 

机构地区：[1]The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area,Department of Biochemistry and Molecular Biology,Shantou University Medical College,Shantou,Guangdong 515041,China [2]Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology,Institute of Oncologic Pathology,Shantou University Medical College,Shantou,Guangdong 515041,China [3]Institute of Basic Medical Science,Cancer Research Center,Shantou University Medical College,Shantou,Guangdong 515041,China [4]Clinical Research Center,Shantou Central Hospital,Shantou,Guangdong 515041,China

出　　处：《Genes & Diseases》2024年第3期55-58,共4页基因与疾病（英文）

基　　金：supported by grants from National Natural ScienceFoundationof China(No.82002975 and No.82173011);Special Fund for Science and Technology of Guangdong Province(No.200105215896551).

摘　　要：Esophageal cancer is one of the leading causes of cancer death in the world,with approximately half of the new cases occurring in China every year.^(1)Esophageal squamous cell carcinoma(ESCC)is the main subtype,accounting for more than 90%,and the five-year survival rate is less than 10%.Using large-scale genome analysis,many driver mutations and key pathways associated with ESCC have been identified.However,these genomic signatures have not improved the clinical management of EscC patients,or established effective targeted therapy.^(2)Esophageal cancer still lacks representative molecular markers.

关 键 词：cancer ESOPHAGEAL ESOPHAGEAL 

分 类 号：R735.1[医药卫生—肿瘤]